Disease · MONDO_0012883

acute promyelocytic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute promyelocytic leukemia. Diseases, record MONDO_0012883. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012883

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute promyelocytic leukemia; Open Targets
Open Targets ID: MONDO_0012883; Open Targets
Other names: AML M3, AML with t(15;17)(q22;q12), AML with t(15;17)(q22;q12);(PML/RARalpha) and variants, APL, APML, APML - acute promyelocytic leukaemia, APML - acute promyelocytic leukemia, FAB M3, acute myeloblastic leukaemia 3, acute myeloblastic leukemia 3, acute myeloblastic leukemia type 3, acute myeloid leukaemia with t(15;17)(q22;q12);(PML/RARalpha) and variants, acute myeloid leukemia M3, acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants, acute promyelocytic leukaemia with PML-rara, acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-rara, acute promyelocytic leukemia with PML-rara, acute promyelocytic leukemia with t(15;17)(q22;q12); PML-rara, leukemia, acute promyelocytic, somatic, promyelocytic leukaemia, promyelocytic leukemia; Open Targets
Disease Ontology: DOID:0060318; Disease Ontology
Disease Ontology: DOID:0081081; Disease Ontology
MeSH: D015473; MeSH
NCI Thesaurus: C3182; NCI Thesaurus
Orphanet: ORPHA:520; Orphanet
Highest stage of its drugs: Approval, for 3 of its 31 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRETINOIN	CHEMBL38	Small molecule	Approval	DailyMed	40	37	37	Drugs and targets
ARSENIC TRIOXIDE	CHEMBL5483015	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	42	36	36	Drugs and targets
GEMTUZUMAB OZOGAMICIN	CHEMBL1201506	Antibody drug conjugate	Approval	ClinicalTrials.gov	7	7	7	Drugs and targets
IDARUBICIN	CHEMBL1117	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
MERCAPTOPURINE	CHEMBL1200751	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
DAUNORUBICIN	CHEMBL178	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DAUNORUBICIN HYDROCHLORIDE	CHEMBL1563	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets83

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	5	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
RARA	Retinoic acid receptor	3	Retinoic acid receptor agonist; Retinoic acid receptor alpha agonist	Approval	https://conductscience.org/library/genes/5914	Drugs and targets
CD33	Myeloid cell surface antigen CD33	2	Myeloid cell surface antigen CD33 binding agent; Myeloid cell surface antigen CD33 other	Approval	https://conductscience.org/library/genes/945	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5426	Drugs and targets

1 to 10 of 83

See all 83 targets

Trials61

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02088541	Selinexor (KPT-330) in Older Patients With Relapsed AML	Phase 2	317	2020-10-08	Acute Myeloid Leukemia (AML)	CYTARABINE, HYDROXYUREA, SELINEXOR	Its record names the disease	ClinicalTrials.gov
NCT02339740	Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia	Phase 3	158	2021-12-16	Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA	ARSENIC TRIOXIDE, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00866918	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia	Phase 3	106	2017-04-04	Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm	ARSENIC TRIOXIDE, CYTARABINE, IDARUBICIN, MERCAPTOPURINE, METHOTREXATE, MITOXANTRONE HYDROCHLORIDE, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00492856	S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia	Phase 3	105	2014-07-18	Leukemia	MERCAPTOPURINE, METHOTREXATE, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00413166	All-trans Retinoic Acid, and Arsenic +/- Idarubicin	Phase 2	78	2019-04-18	Acute Promyelocytic Leukemia	ARSENIC TRIOXIDE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00551460	S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia	Phase 2	78	2017-12-22	Leukemia	ARSENIC TRIOXIDE, GEMTUZUMAB OZOGAMICIN, MERCAPTOPURINE, METHOTREXATE, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT01191541	Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)	Phase 4	65	2021-02-21	Leukemia	ARSENIC TRIOXIDE	Its record names the disease	ClinicalTrials.gov
NCT01404949	Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy	Phase 2	17	2021-11-30	Acute Promyelocytic Leukemia	ARSENIC TRIOXIDE, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00184054	Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia	Phase 2	11	2014-07-17	Acute Myelogenous Leukemia	ARSENIC TRIOXIDE, ASCORBIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00528450	Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia	Phase 2	1	2016-01-29	Leukemia	ARSENIC TRIOXIDE, IDARUBICIN, TRETINOIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 61

See all 61 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Standard Risk vs High Risk: deaths from any cause	1 of 101	0 of 57	158	NCT02339740	Trial comparisons
Standard Risk vs High Risk: serious adverse events	3 of 101	2 of 57	158	NCT02339740	Trial comparisons
Standard Risk vs High Risk: serious adverse events	17 of 66	14 of 35	101	NCT00866918	Trial comparisons

Papers from its trials29

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40825164	RESULT	1	PubMed
27400939	RESULT	1	PubMed
25470713	RESULT	1	PubMed
24127444	RESULT	1	PubMed
23841729	RESULT	2	PubMed
21751984	RESULT	1	PubMed
21385856	RESULT	1	PubMed
20644121	RESULT	1	PubMed
17959855	RESULT	1	PubMed
17116939	RESULT	1	PubMed

1 to 10 of 29

See all 29 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0012883

GET https://conductscience.org/api/diseases/v1/MONDO_0012883/drugs?page=2

API reference For AI assistants